NEWSROOM

Healthcare

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

POMPANO BEACH, Fla., May 29, 2025 - PRISM MediaWire -  BioStem Technologies, Inc.  (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami. Jason Matuszewski, the Company’s CEO, will participate in a fireside chat and will be available for...

read more
Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates

Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates

Issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease JACKSON CENTER, Pa., May 28, 2025 - PRISM MediaWire - Halberd Corporation (OTC: HALB) in cooperation with Athena Telemedicine Partners, LLC, announces astounding clinical efficacy for our patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney...

read more
BioStem Announces Notice of Allowance for Three New U.S. Patent Applications

BioStem Announces Notice of Allowance for Three New U.S. Patent Applications

Expanding patent portfolio reinforces the Company’s commitment to wound care innovation, with 55 issued patents and 52 pending applications POMPANO BEACH, Fla., May 28, 2025 - PRISM MediaWire - BioStem Technologies, Inc.  (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance...

read more
Catheter Precision, Inc. Receives CE Mark for LockeT

Catheter Precision, Inc. Receives CE Mark for LockeT

Opens Multi-Billion Market Opportunity for the Company First Order for 100 Units Received FORT MILL, S.C., May 27, 2025 - PRISM MediaWire - Catheter Precision, Inc. (NYSE American: VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has received CE Mark approval for LockeT, the latest advanced vascular closure device. Receipt of the CE Mark indicates compliance with European Union (EU)...

read more
BioStem Announces Notice of Allowance for Three New U.S. Patent Applications

Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalist

Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future POMPANO BEACH, Fla., May 22, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, CEO of BioStem is an Ernst & Young LLP (EY US) finalist for the prestigious Entrepreneur...

read more
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologies CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 - PRISM MediaWire - Aclarion, Inc.,...

read more
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “we,” “our,” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that topline data from the first two dose cohorts of its ongoing...

read more
American Shared Hospital Services Reports First Quarter 2025 Financial Results

American Shared Hospital Services Reports First Quarter 2025 Financial Results

Reports 17% Year over Year First Quarter Revenue Growth Conference Call Scheduled for 12:00 PM ET Today SAN FRANCISCO, CA, May 15, 2025 - PRISM MediaWire - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its leasing and direct patient care services segments, today announced financial results for the first quarter ended March 31, 2025. Key Financial...

read more
SS Innovations Reports First Quarter 2025 Financial Results

SS Innovations Reports First Quarter 2025 Financial Results

Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3  Fort Lauderdale, FL, May 14, 2025 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three...

read more
American Shared Hospital Services Reports First Quarter 2025 Financial Results

American Shared Hospital Services Announces First Quarter Financial Results Conference Call

Call Scheduled for May 15th at 12:00 PM ET SAN FRANCISCO, May 12, 2025 - PRISM MediaWire - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its leasing and direct patient care services segments, today announced that the Company will hold a conference call to discuss its first quarter 2025 financial results on May 15th at 12:00 pm ET. The first...

read more
BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results

Preliminary net revenue increased 73% to $72.5 million for Q1 2025, compared to $41.9 million in Q1 2024 Achieved preliminary GAAP net income of $4.5 million, or $0.27 per share Reported preliminary Q1 2025 Adjusted EBITDA of $7.8 million Quarter-end cash balance of $26.7 million, up from $22.8 million as of December 31, 2024 Financial results conference call and webcast to be held on May 12, 2025 at 4:30 pm ET POMPANO BEACH, FL, May 12, 2025 - PRISM MediaWire - BioStem Technologies, Inc....

read more
PRISM MarketView Honors Mental Health Awareness Month with a Spotlight on Emerging Innovators

PRISM MarketView Honors Mental Health Awareness Month with a Spotlight on Emerging Innovators

NEW YORK, May 12, 2025 - PRISM MediaWire - In recognition of Mental Health Awareness Month, PRISM MarketView reaffirms its commitment to highlighting the critical importance of mental health and the ongoing efforts to improve mental well-being across the nation. Established in 1949 by Mental Health America, Mental Health Awareness Month serves to educate the public about mental illnesses, promote mental wellness, and reduce the stigma associated with mental health conditions. This year's...

read more
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

Aclarion Announces Texas Back Institute as New CLARITY Trial Site

Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”)...

read more
Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

IRVINE, Calif., May 7, 2025 - PRISM MediaWire - Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. Registration for the live webinar, which will discuss financial results and include Q&A, is required at the following link: Oncocyte Q1...

read more
Ultrack Systems Inc. (OTC: MJLB) Announces Better Pets U.S. Trademark Class Application for Full-Spectrum Pet Wellness Product Line

Ultrack Systems Inc. (OTC: MJLB) Announces Better Pets U.S. Trademark Class Application for Full-Spectrum Pet Wellness Product Line

CONCORD, Ontario, May 07, 2025 - PRISM MediaWire - Ultrack Systems Inc. (OTC: MJLB), an emerging diversified holding company, is pleased to announce that Better Pets, its recent strategic acquisition target under a signed Memorandum of Understanding (MOU), has officially filed a U.S. trademark class application for its expanding line of health-focused pet products. This marks a major milestone in Better Pets’ North American market strategy and supports Ultrack’s commitment to entering the...

read more
SS Innovations Reports First Quarter 2025 Financial Results

SS Innovations Reiterates Guidance for First Quarter 2025 and Provides Commentary on Second Quarter 2025 Order Trends

Press Audio Overview: FORT LAUDERDALE, Fla., May 05, 2025 - PRISM MediaWire -  SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today reiterated guidance for the first quarter of 2025. “Following our recent uplisting to Nasdaq, we remain very pleased with the growth trajectory of our business as we conclude...

read more
Aclarion Welcomes Advocate Health as CLARITY Trial Site

Aclarion Welcomes Advocate Health as CLARITY Trial Site

Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Press Audio: BROOMFIELD, Colo., May 05, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON,...

read more
SS Innovations Reports First Quarter 2025 Financial Results

SS Innovations Announces Chief Financial Officer Transition

Listened: Thomas Wolff · SS Innovations Announces Chief Financial Officer Transition Fort Lauderdale, FL, May 2, 2025 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Arvind Palaniappan as the Company’s Interim Chief Financial Officer, effective May 1, 2025,...

read more
Ultrack Systems Inc. (OTC: MJLB) Announces Better Pets U.S. Trademark Class Application for Full-Spectrum Pet Wellness Product Line

Ultrack Systems Inc. (OTC: MJLB) Signs MOU to Acquire Better Pets, a Leading Health-Focused Pet Product Brand

CONCORD, Ontario, May 01, 2025 - PRISM MediaWire - Ultrack Systems Inc. (OTC: MJLB) ("Ultrack" or the "Company") is pleased to announce it has entered into a Memorandum of Understanding (MOU) to acquire Better Pets, a premium pet wellness company proudly operating under the Better Health Sciences portfolio. This strategic move aligns with Ultrack’s broader mission to diversify and scale its operations into high-growth verticals—leveraging the booming $157 billion U.S. pet industry...

read more
BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem to Showcase its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Spring Meeting

Company to co-exhibit with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three accepted scientific posters will feature BioStem’s advanced allograft portfolio POMPANO BEACH, Fla., May 1, 2025 - PRiSM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced its agenda for the...

read more
BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Host First Quarter 2025 Financial Results Conference Call on May 12, 2025

Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 30, 2025 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will release its first quarter 2025 financial results on Monday, May 12, 2025, and will host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview of the...

read more
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries  Listen: Broomfield, CO, April 29, 2025 – PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help...

read more
SS Innovations Reports First Quarter 2025 Financial Results

SS Innovations to Uplist to Nasdaq

Listened: Fort Lauderdale, FL, April 24, 2025 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company’s common stock has been approved for listing on The Nasdaq Capital Market® ("Nasdaq").  Trading on Nasdaq is expected to commence on April 25, 2025, and the Company’s shares...

read more
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Joint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements in OLP Visible lesion resolution during treatment; return toward baseline post-dosing supports localized activity Listen: PITTSBURGH, April 23, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company...

read more
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Broomfield, CO, April 23, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 12:30 PM ET. Brent Ness, Chief Executive Officer of Aclarion, will...

read more
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement Listen: PITTSBURGH, April 22, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today...

read more
BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies to Present at the Centri Capital Conference

The presentation will be webcast at 10:30 AM ET on April 22, 2025 POMPANO BEACH, Fla., April 21, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, is pleased to announce that its Chief Executive Officer, Jason Matuszewski, will be presenting and holding one-on-one meetings at the upcoming Centri Capital...

read more
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% Listen: BROOMFIELD, Colo., April 21, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians...

read more
PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath

PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath

Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic Programs NEW YORK, April 15, 2025 - PRISM MediaWire - PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc. (“Opus Genetics” or the “Company”) (Nasdaq: IRD), a clinical-stage gene therapy company developing treatments for inherited retinal diseases (IRDs) and broader ophthalmic conditions. Dr. George Magrath, Chief Executive Officer of...

read more
BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

Company reports record preliminary fourth quarter net revenue of $102.9 Million, contributing to a total of $301.8 Million in revenue for 2024 Achieves preliminary GAAP net income of $15.5 million, or $0.94 per share, marking the fourth consecutive quarter of profitability Preliminary Q4 2024 Adjusted EBITDA of $11.1 Million Financial Results Conference Call and Webcast to be held on April 14, 2025 at 4:30 pm ET POMPANO BEACH, FL, April 14, 2025 - PRISM MediaWire - BioStem Technologies, Inc....

read more

Contact Us

PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850